1 Nutt, D. J., King, L. A., Saulsbury, W. & Blakemore, C. Development of a rational scale for assessing the risks of drugs of potential misuse. Lancet 369, 1047–1053 (2007).

2 Nutt, D. J., King, L. A. & Phillips, L. D. Drug harms in the UK: a multicriteria decision analysis. Lancet 376, 1558–1565 (2010).

3 [No authors listed]. Prisons & drug offenders. DrugWarFacts.org [online], (2008).

4 United Nations. Single Convention on Narcotic Drugs. UNODC [online], (1961).

5 United Nations. Convention on Psychotropic Substances. UNODC [online], (1971).

6 United Nations. Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. UNODC [online], (1988).

7 Title 21 United States Code (USC) Controlled Substances Act. www.deadiversion.usdoj.gov[online]

8 Nichols, D. E. Hallucinogens. Pharmacol. Ther. 101, 131–181 (2004).

9 El-Mallakh, R. S. & Abraham, H. D. MDMA (Ecstasy). Ann. Clin. Psychiatry 19, 45–52 (2007).

10 Danovitch, I. & Gorelick, D. A. State of the art treatments for cannabis dependence. Psychiatr. Clin. North Am. 35, 309–326 (2012).

11 Abrams, D. I. et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68, 515–521 (2007).

12 Zajicek, J. P. et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 83, 1125–1132 (2012).

13 The Misuse of Drugs Act (UK). legislation.gov.uk [online], (1971).

14 The Misuse of Drugs Regulations (UK). legislation.gov.uk [online], (2001).

15 Grob, C. S. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71–78 (2011).

16 Strassman, R. J. Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J. Psychoactive Drugs 23, 29–38 (1991).

17 Nutt, D. J. Guerilla psychopharmacology: a new approach to research in challenging areas. Pharmacol. Matters 5, 7–9 (2012).

18 Pertwee, R. G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 30, S13–S18 (2006).

19 Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932–1936 (1990).

20 Reynolds, J. R. On the therapeutic uses and toxic effects of cannabis indica. Lancet 135, 637–683 (1890).

21 Advisory Council on the Misuse of Drugs. Cannabis: classification and public health (2008). gov.uk [online], (2008).

22 Weissenborn, R. & Nutt, D. J. Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? J. Psychopharmacol. 26, 213–220 (2012).

23 Passie, T., Emrich, H. M., Karst, M., Brandt, S. D. & Halpern, J. H. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test. Anal. 4, 649–659 (2012).

24 Strohbeck-Kuehner, P., Skopp, G. & Mattern, R. Cannabis improves symptoms of ADHD. Cannabinoids 3, 1–3 (2008).

25 Englund, A. et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 27, 19–27 (2013).

26 Morgan, C. J. A., Freeman, T. P., Schafer, G. L. & Curran, H. V. Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35, 1879–1885 (2010).

27 Pertwee, R. G. et al. The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo. Br. J. Pharmacol. 150, 586–594 (2007).

28 National Institutes of Health Guide. Announcement of the department of health and human services' guidance on procedures for the provision of marijuana for medical research. NIH Guide [online], (1999).

29 King, L. Are current attempts to control new synthetic cannabinoids futile? DrugScience (online), (2012).

30 Loewinger, G. C., Oleson, E. B. & Cheer, J. F. Using dopamine research to generate rational cannabinoid drug policy. Drug Test. Anal. 5, 22–26 (2013).

31 Stella, N. & Kline, T. Composition and methods of treating glioblastoma. World Intellectual Property Organisation Publication Number WO 2012/024670 A2 (2012).

32 Grinspoon, L. & Bakalar, J. B. Psychedelic Drugs Reconsidered (Basic Books, 1979).

33 Grinspoon, L. & Bakalar, J. B. Can drugs be used to enhance the psychotherapeutic process? Am. J. Psychother. 40, 393–404 (1986).

34 Greer, G. R. & Tolbert, R. A method of conducting therapeutic sessions with MDMA. J. Psychoactive Drugs 30, 371–379 (1998).

35 Ricaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J. & McCann, U. D. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (ecstasy). Science 297, 2260–2263 (2002); retraction Science 301, 1479 (2003).

36 Advisory Council on the Misuse of Drugs. MDMA (ecstasy): a review of its harms and classification under the Misuse of Drugs Act 1971. gov.uk [online], (2009).

37 Green, A. R., O'Shea, E. & Colado, M. I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol. 500, 3–13 (2004).

38 King, L. A. & Corkery, J. M. An index of fatal toxicity for drugs of misuse. Hum. Psychopharmacol. 25, 162–166 (2010).

39 Nutt, D. J. Equasy — an overlooked addiction with implications for the current debate on drug harms. J. Psychopharmacol. 23, 3–5 (2009).

40 Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L. & Doblin, R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 25, 439–452 (2010).

41 Mithoefer, M. C. et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J. Psychopharmacol. 27, 28–39 (2013).

42 Bedi, G., Luan Phan, K., Angstadt, M. & de Wit, H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl.) 207, 73–83 (2009).

43 Bedi, G., Hyman, D. & de Wit, H. Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol. Psychiatry 68, 1134–1140 (2010).

44 Huot, P. et al. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J. Neurosci. 31, 7190–7198 (2011).

45 Edut, S., Rubovitch, V., Schreiber, S. & Pick, C. G. The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI) Psychopharmacology 214, 877–889 (2011).

46 Gladstone, D. J. & Black, S. E. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can. J. Neurol. Sci. 27, 97–105 (2000).

47 Nutt, D. J. Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. Adv. Psychopharmacol. 1, 35–36 (2011).

48 Bird, S. Mephedrone and cocaine: clues from Army testing. Straight Statistics [online], (2011).

49 Lee, M. A. & Shlain, B. Acid Dreams: The Complete Social History of LSD, the CIA, the Sixties and Beyond 93 (Grove, 1985).

50 Masters, R. & Houston, J. The Varieties of Psychedelic Experience: The Classic Guide to the Effects of LSD on the Human Psyche (Park Street, 1971).

51 Krebs, T. & Johansen, P.-Ø. Lysergic acid diethylamide (LSD) for alcoholism: a meta-analysis of controlled trials. J. Psychopharmacol. 26, 994–1002 (2012).

52 Grof, S. LSD Psychotherapy 4th edn (Multidisciplinary Association for Psychedelic Studies, 2001).

53 Drugs Act 2005 (UK). legislation.gov.uk [online], (2005).

54 Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J. Clin. Psychiatry 67, 1735–1740 (2006).

55 Sewell, R. A., Halpern, J. H. & Pope, H. G. Jr. Response of cluster headache to psilocybin and LSD. Neurology 66, 1920–1922 (2006).

56 Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl.) 187, 268–283 (2006).

57 Griffiths, R., Richards, W., Johnson, M., McCann, U. & Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 22, 621–632 (2008).

58 Weber, E. T. & Andrade, R. Htr2a gene and 5-HT2A receptor expression in the cerebral cortex studied using genetically modified mice. Front. Neurosci. 4, 36 (2010).

59 Friston, K. J. & Kiebel, S. J. Cortical circuits for perceptual inference. Neural Netw. 22, 1093–1104 (2009).

60 Andrade, R. Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology 61, 382–386 (2011).

61 Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, A. H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897 (1998).

62 Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl Acad. Sci. USA 109, 2138–2143 (2012).

63 Carhart-Harris, R. L. Using MEG to characterise the mechanism of action of psilocybin in human volunteers. Br. Neurosci. Assoc. Abstr. 22, P3-D-092 (2013).

64 Carhart-Harris, R. L. et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br. J. Psychiatry 200, 238–244 (2012).

65 Carhart-Harris, R. L. et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr. Bull. 8 Oct 2012 (doi:10.1093/schbul/sbs117).

66 Robbins, T. R., Everitt, B. & Nutt, D. J. The Neurobiology of Addiction: New Vistas (OUP, 2010).

67 Stotts, A. L., Dodrill, C. L. & Kosten, T. R. Opioid dependence treatment: options in pharmacotherapy. Expert Opin. Pharmacother. 10, 1727–1740 (2009).

68 United Kingdom House of Commons Hansard Debates for November 19th 2012. www.publications.parliament.uk[online], (2012).

69 Michelman, S. & Rorty, J. Doing Kimbrough justice: implementing policy disagreements with the federal sentencing guidelines. Suffolk U. L. Rev. 45, 4 (2012).

70 The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2010 (UK). legislation.gov.uk [online], (2010).

71 Karst, M., Halpern, J. H., Bernateck, M. & Passie, T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 30, 1140–1144 (2010).

72 Kiefer, R. T. et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. 9, 1173–1201 (2008).

73 Fibiger, C. Psychopharmacology in crisis. Schizophr. Bull. 38, 649–650 (2012).

74 Morgan, C. J., Curran, H. V. & the Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction 107, 27–38 (2012).

75 Coppola, M. & Mondola, R. Methoxetamine: from drug of abuse to rapid-acting antidepressant. Med. Hypotheses 79, 504–507 (2012).